New cancer drug trial halted early – what we know
NCT ID NCT05194072
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug, felmetatug vedotin, alone or with pembrolizumab, in people with advanced solid tumors like ovarian, breast, and lung cancer. The goal was to check safety and find the right dose. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AdventHealth Celebration Infusion Center
Celebration, Florida, 34747, United States
-
AdventHealth Medical Group Oncology Research at Celebration
Celebration, Florida, 34747, United States
-
Community Health Network, Inc.
Indianapolis, Indiana, 46227, United States
-
Community Health Network, Inc.
Indianapolis, Indiana, 46250, United States
-
Community Health Network, Inc.
Indianapolis, Indiana, 46256, United States
-
Florida Cancer Specialists
Orlando, Florida, 32827, United States
-
Hamato-Onkologische Phase 1 Unit der Charite/Charite Research Organisation
Berlin, 12200, Germany
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Mayo Clinic Florida
Jacksonville, Florida, 32224, United States
-
Northwestern Medical Group
Chicago, Illinois, 60611, United States
-
Northwestern Memorial Hospital
Chicago, Illinois, 60611, United States
-
Presbyterian/St Lukes Medical Center
Denver, Colorado, 80218, United States
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
START Madrid-Hospital Universitario HM Sanchinarro
Madrid, 28050, Spain
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
START Mountain Region
West Valley City, Utah, 84119, United States
-
Sarah Cannon Research Institute
London, W1G 6AD, United Kingdom
-
Sarah Cannon Research Institute - Pharmacy
Nashville, Tennessee, 37203, United States
-
Sarah Cannon Research Institute at Florida Cancer Specialists
Orlando, Florida, 32827, United States
-
South Texas Accelerated Research Therapeutics, LLC
San Antonio, Texas, 78229, United States
-
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, K1H 8L6, Canada
-
The University of Texas M.D. Anderson Cancer Center
Houston, Texas, 77030, United States
-
The University of Texas MD Anderson Cancer Center Investigational Pharmacy Services
Houston, Texas, 77030, United States
-
UCHealth Sue Anschutz-Rodgers Eye Center
Aurora, Colorado, 80045, United States
-
University of Colorado Hospital - Anschutz Cancer Pavilion (ACP)
Aurora, Colorado, 80045, United States
-
University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)
Aurora, Colorado, 80045, United States
-
University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)
Aurora, Colorado, 80045, United States